{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-030900","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2026-09-22T20:05:55+00:00","discovered_at":"2026-09-22T20:07:00.445060+00:00","generated_at":"2026-09-22T20:07:16.328755+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aytu Q4 FY26 revenue up 6.4% to $16.1M; EXXUA launches with 3,323 scripts","bullets":["Q4 FY26 net revenue $16.1M, +6.4% YoY; EXXUA alone contributed $3.9M in first full quarter.","EXXUA Q4 prescriptions 3,323, up ~138% from Q3; June hit record 1,261 scripts; shipments ~4,600 units.","Full-year FY26 revenue $57.6M, down 13.3% YoY, driven by ADHD portfolio decline and Adzenys generic competition.","FY26 net loss $14.3M ($1.16 loss/share) vs $13.6M loss; Adjusted EBITDA -$3.7M vs +$9.2M prior year.","Cash $26.3M at June 30, 2026; warrant amendment cut derivative warrant liabilities by $26.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-030900","json":"https://secwatch.observer/filing/0001437749-26-030900.json","markdown":"https://secwatch.observer/filing/0001437749-26-030900.md","text":"https://secwatch.observer/filing/0001437749-26-030900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/0001437749-26-030900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926030900/aytu20260502_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-22T20:07:16.328755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}